Clinical Trial Update: NWRD06 DNA Plasmid for HCC After Curative Resection. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating NWRD06 DNA plasmid for hepatocellular carcinoma after curative resection is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• NWRD06 DNA Plasmid (NWRD06 DNA Plasmid)

Snippet

Sponsor: Newish Technology (Beijing) Co., Ltd. | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING